Angiotensin II is recognised as the principle active peptide of the renin-angiotensin system, exerting effects on fluid and electrolyte homeostasis, and cardiovascular control including neural and long term trophic effects. However, recent studies indicate that other angiotensin peptides such as angiotensin III, angiotensin II (1-7) and angiotensin IV, may have specific actions. Interestingly, recent work involving angiotensin IV demonstrates that this peptide binds to specific receptors and may be Keywords: angiotensin metabolites; angiotensin III; angiotensin II(1-7); angiotensin IV; globin
Bioactive angiotensin peptides
The renin-angiotensin system (RAS) was initially identified as a circulating humoral system with the effector peptide, angiotensin II (Ang II), generated by an enzymatic cascade. Angiotensinogen, which is synthesized in the liver, is cleaved by renin, a product of the juxtaglomerular cells of the kidney, to form Ang I, which in turn is cleaved by angiotensinconverting enzyme (ACE) to form Ang II. ACE is membrane bound and predominates on the endothelial cells of all vascular beds. Apart from the production of Ang II in plasma, Ang II, renin and ACE have all been described in tissues such as the brain, kidney, adrenal, vasculature, heart and ovaries. This suggests a separate and distinct RAS in these tissues and implies endocrine, paracrine and autocrine roles for Ang II. 1 
Actions of Ang II
Ang II regulates blood pressure, fluid volume homeostasis and pituitary hormone release via AT 1 and AT 2 receptors located in the kidney, adrenal gland, and the cardiovascular and nervous systems. [2] [3] [4] [5] In the kidney, for instance, Ang II acts on renal vessels, glomeruli, tubules and renomedullary interstitial cells, to alter renal blood flow, glomerular filtration rate and electrolyte reabsorption. [6] [7] [8] [9] Ang II also acts on the adrenal cortex to stimulate aldosterone secretion and hence renal sodium reabsorption. 10 Ang II is a potent vasoconstrictor, acting directly on vascular smooth muscle and indirectly via facilitation of noradrenaline release from sympathetic terminals. 11, 12 In the heart, Ang II exerts positive iono- tropic and chronotropic effects and facilitates sympathetic activity. 13 Acting on the brain, Ang II induces fluid and salt ingestion, modulates neuroendocrine systems, including vasopressin and corticotropin releasing factor release, and interacts with the autonomic control of the cardiovascular system to influence blood pressure. 3, 14, 15 In many instances, these effects are complementary to those of the systemic peptide on peripheral target organs. Thus, systematic Ang II affects the brain through AT 1 receptors located in the circumventricular organs, regions with a deficient blood brain barrier. In addition, endogenous neurally derived Ang II appears to act at many central nervous system sites behind the blood brain barrier. [16] [17] [18] Most of the classical actions of Ang II are mediated via the AT 1 receptor whereas AT 2 receptor stimulation may cause opposing effects. This was observed in rat coronary endothelial cells, in which AT 2 receptor stimulation blocks the proliferative effect mediated by the AT 1 receptor 19 and in neuronal cultures, where AT 1 and AT 2 receptors mediate opposing actions on potassium currents.
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Ang II metabolism
Ang II is rapidly metabolised in the circulation 21 and in the cerebral ventricles. 22 The aminopeptidases A and N sequentially remove amino acids from the N-terminus of Ang II to form the fragments Ang II(2-8), also known as Ang II, and Ang II (3) (4) (5) (6) (7) (8) , also known as Ang IV. 23 Ang II(1-7) is another metabolite of Ang II 24 but may be cleaved directly from Ang I [24] [25] [26] by neutral endopeptidase 24.11 and prolyl endopeptidase. 27 Of these metabolites, Ang III binds with the highest affinity to AT 1 receptors (10-fold lower affinity than Ang II) whilst both Ang IV and Ang II(1-7) bind weakly with affinities of a 100-to 1000-fold less. 28 
Ang III
Ang III exhibits some of the classical actions of Ang II such as stimulating aldosterone secretion, vasoconstriction, pressor and dipsogenic activity. [29] [30] [31] In addition to these studies, recent findings suggest that Ang III may be an important agonist, if not the final mediator of some actions of Ang II. 23, [32] [33] [34] This was clearly shown in the study by Zini et al, 23 in which the use of a specific antagonist of aminopeptidase A, demonstrated that the central action of Ang II on vasopressin secretion in rats is dependent on its prior conversion to Ang III.
In contrast to the actions associated with Ang III, initial work involving other Ang II metabolites, such as Ang II (1-7) and Ang IV, resulted in the belief that these peptides were functionally inactive. 29, 30, 35 However, subsequently, both Ang II(1-7) and Ang IV have been associated with a number of actions.
Ang II(1-7)
An Ang II(1-7) binding site that is distinct from Ang II receptors, has not yet been clearly described and is complicated by Ang II(1-7) eliciting some actions similar to those of Ang II. For instance, Ang II (1-7) and Ang II stimulated vasopressin secretion 36 and excited paraventricular hypothalamic neurons and were inhibited by the partial antagonist of the AT 2 receptor, CGP 42112A. 37 Also, Ang II(1-7) and Ang II excited the same nucleus tractus solitarius cells although several cells were only stimulated by one peptide. 38 Furthermore, microinjection of Ang II(1-7) and Ang II into the rostral ventrolateral medulla caused a pressor effect with the effect of Ang II(1-7), but not Ang II, being inhibited by the Ang II(1-7) specific antagonist, A-799. [39] [40] [41] These latter studies suggest that Ang II(1-7) might exert functions which are distinct from Ang II actions through a novel Ang II(1-7) binding site. In support of this, lateral cerebroventricular administration of an Ang II(1-7) antibody, dose-dependently increased blood pressure in the Ren-2 transgenic hypertensive rats, the opposite to that observed with an Ang II antibody. 42 Also, in contrast to Ang II, Ang II(1-7) is a vasodilator in porcine, 43 canine 44 and feline 45 vessels, possibly via nitric oxide, although prostaglandins may be involved [46] [47] [48] [49] [50] 44, 51 The signalling mechanisms involved with the Ang II(1-7) actions are also different to those of Ang II since the heptapeptide does not activate phospholipase C or release inositol phosphates in astrocytes, 47, 52 or activate phospholipase D, produce diacylglycerol or increase intracellular Ca 2+ in vascular smooth muscle cells. 50, 53, 54 However, Ang II(1-7) has been associated with increased phospholipase A2 activity in renal proximal tubular cells. 55 From numerous studies, it appears that there may be a distinct Ang II(1-7) receptor, the physiological significance of which may be further characterised by the Ang II(1-7) specific antagonist A-799.
Ang IV
Recent work has focused on Ang IV due to the wide distribution of a pharmacologically distinct binding site, specific for the peptide and designated the AT 4 receptor. 56, 57 This binding site shows high selectivity for Ang IV followed by Ang III (10-fold lower affinity) ӷ Ang II, [Sar 1   Ile   8 ] Ang II ӷ losartan, PD 123177 and CGP 42112A. [58] [59] [60] [61] [62] The AT 4 receptor also displays a distinct distribution pattern, being found in the cholinergic areas and motor and sensory regions in the brain. 59, 63 It is also found in the heart, 60 adrenal cortex, 57,64 vascular smooth muscle cells, 61 and numerous other tissues. 65 One of the first actions attributed to Ang IV was its ability to increase memory recall in passive 66, 67 and conditioned avoidance response studies. 66 This cognitive effect of Ang IV was thought to be via the hippocampus since intracerebroventricular administration of Ang IV induces c-fos expression in hippocampal pyramidal cells. 68 In addition, central injection of Ang IV in the rat, enhances apomorphine-induced stereotypy. 66 Also, Ang IV inhibited neurite outgrowth from cultured embryonic day 11 (E11) chicken paravertebral sympathetic neurons by 25% 69 and therefore may have a potential role in neuronal development.
Several studies have focused on the ability of Ang IV to dilate vessels. In the rabbit, Ang IV caused vasodilatation of pial arterioles, only if given subsequent to L-arginine administration, suggesting an involvement of nitric oxide. 70 Infusion of Ang IV into the middle cerebral artery of the rat increased cerebral blood flow by 20% 65 although in another study, Ang IV had no effect on cerebral blood flow in control animals, but in rats with experimental subarachnoid haemorrhage and vasospasm, infusion of Ang IV returned blood flow to baseline levels. 71 This effect was not inhibited by a nitric oxide synthase inhibitor. 71 Infusion of Ang IV into the rat renal artery increased renal cortical blood flow. 57 Whilst these studies do lend support for a role of Ang IV in vasodilatation, others observed Ang IV mediated vasoconstriction, probably via the AT 1 receptor. [72] [73] [74] [75] [76] In addition to these vascular effects, Ang IV increased the expression of plasminogen activator inhibitor-1 (PAI-1) mRNA in bovine aortic endothelial cells. 77 Ang IV also stimulated DNA synthesis in rat anterior pituitary cells 78 and stimulated DNA and RNA synthesis in cultures of rabbit fibroblasts. 79 Furthermore, the peptide synergistically enhanced basic fibroblast growth factor induced DNA synthesis in cultured bovine endothelial cells. 62 Nle 1 -Ang IV, an Ang IV agonist, decreased c-fos and egr 1 mRNA in the mechanically loaded, isolated rabbit heart. 80 Only sparse evidence exists regarding second messengers associated with the AT 4 receptor. In the mouse neuroblastoma cell line, NG108-15 81 and E18 chicken myocytes, 82 Ang IV did not alter intracellular Ca 2+ levels although Ang IV did inhibit an Ang II induced increase in protein synthesis and intracellular Ca 2+ in E18 chicken myocytes. 82 In contrast to these studies, in rat vascular smooth muscle cells, Ang IV produced a small but sustained increase in intracellular Ca 2+ via extracellular influx, and an increase in inositol phosphates 83 whilst in opossum kidney cells, Ang IV stimulated a transient increase in intracellular levels of Ca 2+ (via voltage-sensitive channels), independent of inositol-phosphates. 84 Furthermore, in opossum kidney cells, Ang IV neither produced an alteration in basal, or atrial natriuretic factor stimulated guanylate cyclase activity, nor basal or forskolin activated adenylate cyclase levels. 84 Whether Ang IV is the true ligand for the AT 4 receptor is doubtful since the localisation of the components of the RAS, in brain areas which include the circumventricular organs and the nucleus of the solitary tract, do not correspond with the distribution of the AT 4 receptor, whilst the AT 4 receptor and not RAS components are found in the basal nucleus of Meynert, the red nucleus, motor trigeminal and facial nuclei. 63 This considerable mismatch in the central nervous system, between the distribution of the AT 4 receptor and RAS components, leads us to propose that Ang IV may not be the native ligand for the AT 4 receptor. We have recently identified an alternative ligand for the AT 4 receptor, a decapeptide which is identical to an internal sequence of the sheep (amino acids [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] and human (amino acids 32-41) ␤ globin which we extracted from sheep brain using an AT 4 radioreceptor binding assay and a multistep protein purification procedure. 85 This abundant peptide (approximately 2 nmol of peptide per gram of tissue) and Ang IV share very high affinity for the AT 4 receptor with their binding sites exhibiting very similar affinities for competing ligands and both peptides displayed very similar binding patterns. 85 The globin fragment has previously been isolated from different brain regions [86] [87] [88] [89] and has been termed LVV-haemorphin-7. Furthermore, the enzymes pepsin, 90 trypsin 88 and a high molecular weight aspartic proteinase present in bovine brain, 91 are capable of cleaving the decapeptide from globin and is suggestive of processing in the central nervous system. Apart from inhibiting opioid activity, 90 our studies indicate that LVV-haemorphin-7 also inhibits neurite outgrowth from E11 chicken sympathetic neurons and stimulates DNA synthesis in neuronal cultures (unpublished observations). Therefore, ␤ globin may be a precursor of a new family of neuropeptides, some of which bind to the widely distributed AT 4 receptor.
Conclusion
For many years, most work has revolved around Ang II and its important role in the regulation of blood pressure and fluid volume. However, recent work suggests that Ang II metabolites may also be of physiological importance. Indeed, it appears that Ang III may be important in the actions that have formerly been attributed to Ang II, especially in the brain. Furthermore, Ang II(1-7) may play a role in modulating blood pressure via the central nervous system and peripheral tissues, particularly in states where the RAS is markedly activated. In addition, receptors characterised by a high affinity for Ang IV, have a widespread distribution in central and peripheral tissues, raising the possibility of important actions. Our finding of another peptide ligand, LVVhaemorphin-7, in the brain, suggests this receptor may be part of a novel neuropeptide system, possibly involved in memory and neural development. As a result of these ongoing studies, the RAS is emerging as a system with multiple effector peptides with diverse functions.
